Categories
Blood Cancer

The influence of bridging therapy on outcomes in large B-cell lymphoma [Video]

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the use of bridging therapy in a real world setting for patients with large B-cell lymphoma (LBCL) receiving axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T-cell therapy. Stabilization of disease prior to treatment is associated with improved patients outcomes, independent of type of bridging therapy. However, investigational use of polatuzumab vedotin with rituximab and bendamustine as bridging therapy did not result in superior outcomes compared to other bridging regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Meta-analysis of cilta-cel in patients with R/R multiple myeloma [Video]

Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, is currently being investigated in patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207). Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of findings from a meta-analysis of cilta-cel verus the standard of care. Data from various real world registries and clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134), were analyzed and patients receiving cilta-cel had superior progression-free survival and overall survival. Despite cilta-cel causing more adverse events, patients overall reported a better quality of life. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Medical Marijuana

New Commission to prepare Rochester for budding marijuana economy [Video]

Mayor-elect Malik Evans held a press conference Tuesday afternoon to announce details regarding the new Rochester Cannabis Preparation Commission.READ MORE:https://www.rochesterfirst.com/marijuana/watch-live-mayor-elect-malik-evans-announces-rochester-cannabis-preparation-commission/